Skip to main content
Premium Trial:

Request an Annual Quote

Alnylam Signs Deal with Merck to Develop RNAi Therapeutics

NEW YORK, Sept. 9 (GenomeWeb News) - Alnylam Holdings has signed on to a collaboration with Merck in order to further develop RNA interference technology and develop RNAi-based therapeutics, the companies said today.

 

Under the agreement, Merck will provide to Alnylam, of Cambridge, Mass., its own validated drug targets, and Alnylam will develop RNAi compounds against the targets. After the preclinical development phase, Merck and Alnylam will then decide which of the companies, or both companies, will take the compounds through the clinical development and marketing phase, the companies said.

 

Both companies said they will offer their resources to the collaboration, although they did not disclose the financial terms of the deal.

 

Alnylam has previously said it would have RNAi-based compounds in the clinic within two to three years.

The Scan

Another Resignation

According to the Wall Street Journal, a third advisory panel member has resigned following the US Food and Drug Administration's approval of an Alzheimer's disease drug.

Novavax Finds Its Vaccine Effective

Reuters reports Novavax's SARS-CoV-2 vaccine is more than 90 percent effective in preventing COVID-19.

Can't Be Used

The US Food and Drug Administration says millions of vaccine doses made at an embattled manufacturing facility cannot be used, the New York Times reports.

PLOS Papers on Frozen Shoulder GWAS, Epstein-Barr Effects on Immune Cell Epigenetics, More

In PLOS this week: genome-wide association study of frozen shoulder, epigenetic patterns of Epstein-Barr-infected B lymphocyte cells, and more.